Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician

Peter J. Angell, Neil Chester, Nick Sculthorpe, Greg Whyte, Keith George, John Somauroo

Research output: Contribution to journalArticle

Abstract

The use of performance-enhancing and social drugs by athletes raises a number of ethical and health concerns. The World Anti-Doping Agency was constituted to address both of these issues as well as publishing a list of, and testing for, banned substances in athletes. Despite continuing methodological developments to detect drug use and associated punishments for positive dope tests, there are still many athletes who choose to use performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the wellbeing of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.
Original languageEnglish
Pages (from-to)78-84
Number of pages7
JournalBritish Journal of Sports Medicine
Volume46
Issue numberSuppl I
DOIs
Publication statusPublished - Nov 2012
Externally publishedYes

Cite this

Angell, Peter J. ; Chester, Neil ; Sculthorpe, Nick ; Whyte, Greg ; George, Keith ; Somauroo, John. / Performance enhancing drug abuse and cardiovascular risk in athletes : implications for the clinician. In: British Journal of Sports Medicine. 2012 ; Vol. 46, No. Suppl I. pp. 78-84.
@article{26e3374656b74f9abee4401b1f2342d9,
title = "Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician",
abstract = "The use of performance-enhancing and social drugs by athletes raises a number of ethical and health concerns. The World Anti-Doping Agency was constituted to address both of these issues as well as publishing a list of, and testing for, banned substances in athletes. Despite continuing methodological developments to detect drug use and associated punishments for positive dope tests, there are still many athletes who choose to use performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the wellbeing of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.",
author = "Angell, {Peter J.} and Neil Chester and Nick Sculthorpe and Greg Whyte and Keith George and John Somauroo",
year = "2012",
month = "11",
doi = "10.1136/bjsports-2012-091186",
language = "English",
volume = "46",
pages = "78--84",
journal = "British Journal of Sports Medicine",
issn = "0306-3674",
publisher = "BMJ Publishing Group",
number = "Suppl I",

}

Performance enhancing drug abuse and cardiovascular risk in athletes : implications for the clinician. / Angell, Peter J.; Chester, Neil; Sculthorpe, Nick; Whyte, Greg; George, Keith; Somauroo, John.

In: British Journal of Sports Medicine, Vol. 46, No. Suppl I, 11.2012, p. 78-84.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Performance enhancing drug abuse and cardiovascular risk in athletes

T2 - implications for the clinician

AU - Angell, Peter J.

AU - Chester, Neil

AU - Sculthorpe, Nick

AU - Whyte, Greg

AU - George, Keith

AU - Somauroo, John

PY - 2012/11

Y1 - 2012/11

N2 - The use of performance-enhancing and social drugs by athletes raises a number of ethical and health concerns. The World Anti-Doping Agency was constituted to address both of these issues as well as publishing a list of, and testing for, banned substances in athletes. Despite continuing methodological developments to detect drug use and associated punishments for positive dope tests, there are still many athletes who choose to use performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the wellbeing of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.

AB - The use of performance-enhancing and social drugs by athletes raises a number of ethical and health concerns. The World Anti-Doping Agency was constituted to address both of these issues as well as publishing a list of, and testing for, banned substances in athletes. Despite continuing methodological developments to detect drug use and associated punishments for positive dope tests, there are still many athletes who choose to use performance and image enhancing drugs. Of primary concern to this review are the health consequences of drug use by athletes. For such a large topic we must put in place delimitations. Specifically, we will address current knowledge, controversies and emerging evidence in relation to cardiovascular (CV) health of athletes taking drugs. Further, we delimit our discussion to the CV consequences of anabolic steroids and stimulant (including amphetamines and cocaine) use. These drugs are reported in the majority of adverse findings in athlete drug screenings and thus are more likely to be relevant to the healthcare professionals responsible for the wellbeing of athletes. In detailing CV health issues related to anabolic steroid and stimulant abuse by athletes we critique current research evidence, present exemplar case studies and suggest important avenues for on-going research. Specifically we prompt the need for awareness of clinical staff when assessing the potential CV consequences of drug use in athletes.

U2 - 10.1136/bjsports-2012-091186

DO - 10.1136/bjsports-2012-091186

M3 - Article

VL - 46

SP - 78

EP - 84

JO - British Journal of Sports Medicine

JF - British Journal of Sports Medicine

SN - 0306-3674

IS - Suppl I

ER -